PHASE I STUDY OF PHOTODYNAMIC THERAPY FOR SURFACE MALIGNANCIES

光动力疗法涉及使用光激活化合物 其定位于肿瘤中，随后通过以下方式激活该化合物： 用于治疗癌症的细胞毒性作用。 当前 方案使用静脉内施用Photofrin II 血卟啉衍生物的制备，目前唯一的 批准用于人类的光敏剂。 其次是 使用光纤将光传送到受影响的区域 氩/泵浦染料激光器。 血卟啉衍生物选择性 与某些正常组织相比，它位于肿瘤中。 选择性 结合聚焦光的光敏剂保留 递送到所涉及的区域允许选择性地破坏肿瘤 而对未涉及的正常组织的影响最小。 血啉 衍生光动力疗法在临床上可用于许多 肿瘤累及的解剖部位。

Photodynamic therapy involves the use of a light activated compound which localizes in tumor, followed by the activation of this compound by light for cytotoxic effects for the treatment of cancer. The current protocol uses the intravenous administration of the Photofrin II preparation of the hematoporphyrin derivative, the only currently approved photosensitizer for use in humans. This is followed by the delivery of light to the affected area using optical fibers coupled to an argon/pumped dye laser. Hematoporphyrin derivative selectively localizes in tumor compared to certain normal tissues. Selective retention of the photosensitizer in combination with focal light delivery to the involved area permits selective destruction of tumor with minimal effect on uninvolved normal tissue. Hematoporphyrin derivative photodynamic therapy may be clinically useful in a number of anatomic sites involved by tumor.